Taiwan Liposome Company, Ltd. (TLC) |
| 7 0 (0%) 04-24 15:47 |
| Open: | 7 |
| High: | 7.09 |
| Low: | 7 |
| Volume: | 12,421 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | NASDAQ Global Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 51.73 |
| Resistance 1: | 44.29 |
| Pivot price: | 42.78 |
| Support 1: | 42.49 |
| Support 2: | 41.38 |
| 52w High: | 7.7 |
| 52w Low: | 4.07 |
Financials
| EPS | 2.830 |
| Book Value | 23.530 |
| PEG Ratio | 5.74 |
| Gross Profit | 3.812 |
| Profit Margin (%) | 39.85 |
| Operating Margin (%) | 32.72 |
| Return on Assets (ttm) | 2.8 |
| Return on Equity (ttm) | 11.8 |
Company news
Tue, 09 Sep 2025
Liposome Drug Delivery Market Size, Share & Growth Forecast 2035 - Research Nester
Thu, 12 Oct 2023
Post-Surgical Pain Market to Register Incremental Growth - openPR.com
Mon, 13 Jun 2022
TLC Announces TLC599 Agreement with Endo - Yahoo Finance
Mon, 13 Jun 2022
Endo Executes Agreement With TLC to Commercialize Phase 3 Orthopedic Product for the Treatment of Osteoarthritis Knee Pain - PR Newswire
Mon, 05 Jul 2021
TLC Announces Details of Stock Swap Transactions - GlobeNewswire
Wed, 30 Jun 2021
Postoperative Pain Market to Rising Steadily at a 7.93% CAGR Owing to Growing Number of Surgeries, During the Study Period [2018-2030], Says DelveInsight - PR Newswire
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
